NASDAQ:RCUS
Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage
Arcus Biosciences shares rose nearly 5% on Tuesday after Goldman Sachs upgraded the biotech to “Buy” and lifted its price target. The stock was up 4.8% at $22.32 in early afternoon trading.
Company hubNASDAQ:RCUS
Arcus Biosciences (RCUS) Stock News & Analysis
Follow the latest Arcus Biosciences (RCUS) company news, earnings coverage and investor analysis from TechStock².
Save this hub to your TS2 Signalbook account.
- Latest update
- Articles in this hub
- 1
- Last 30 days
- 0
What investors are watching
- Earnings, guidance and financial performance
- Valuation, trading activity and market sentiment
- Strategy, catalysts and company-specific risks
All coverage